GlassScriptPhysician profile
Carolyn Quan
NPI 1154351427
$1,040.52
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2024: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $196.70 | 2019 | |
| Astellas Pharma US INC | $188.24 | 2019 | |
| Gilead Sciences, INC. | $132.24 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $123.92 | 2019 | |
| Vifor Pharma, INC. | $93.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $70.10 | 2019 | |
| Csl Behring | $59.00 | 2019 | |
| Merck Sharp & Dohme LLC | $52.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.03 | 2019 | |
| Pfizer INC. | $26.90 | 2019 | |
| Novo Nordisk INC | $22.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.27 | 2019 | |
| Mylan Specialty L.P. | $12.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Quan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.